

The monthly European Industrial Pharmacists' newsletter • March 2020




Technology & Production

A new virus looking for effective treatments

Pharmaceutical companies and health authorities launched an enormous effort of R&D to identify medicines and vaccines against the Covid-19 infection immediately after the first Chinese outbreak of the pandemic. A brief outlook of the main ongoing activities

[Read more...](#)



Politics & Business

The impact of Covid-19 on drug shortages

There may be a direct link between Covid-19 and possible drug shortages, as the current global lockdown is greatly impacting on the regular functioning of the international pharmaceutical hubs and supply chains in China, India, Italy and other European countries. The situation is evolving rapidly and needs accurate monitoring

[Read more...](#)



Regulatory

Time to innovate the EU variation system

The current regulatory system is not reflecting anymore the availability of new digital technologies that may help to optimise the management of minor variations and it should be completely revised, says a report from Medicines for Europe

[Read more...](#)



Focus on EU's Countries

The Netherlands: Innovation in the academia and the industry

The Dutch system for life sciences is rich of many pharmaceutical and biotech companies, universities and R&D centers working to develop innovative treatments using new models of research and new technologies such as gene therapy

[Read more...](#)



EIPG

EIPG: Message from the President and Advisory Group on Competencies

Prof Claude Farrugia writes to all EIPG's members to sustain them in their important role related to the containment of the coronavirus epidemic. A summary of results of the work done by the Advisory group on Competencies is also provided

[Read more...](#)